Ellsworth Advisors LLC Buys Shares of 97,208 Exelixis, Inc. $EXEL

Ellsworth Advisors LLC bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 97,208 shares of the biotechnology company’s stock, valued at approximately $3,589,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Exelixis by 32.2% in the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 1,328 shares in the last quarter. Park Avenue Securities LLC grew its position in Exelixis by 10.6% in the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock valued at $272,000 after acquiring an additional 707 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Exelixis by 23.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock valued at $9,159,000 after acquiring an additional 47,845 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in Exelixis in the 1st quarter valued at about $233,000. Finally, Concurrent Investment Advisors LLC acquired a new position in Exelixis in the 1st quarter valued at about $457,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent research reports. Benchmark reiterated a “neutral” rating on shares of Exelixis in a research note on Monday, June 23rd. Truist Financial decreased their price objective on Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. Royal Bank Of Canada decreased their price objective on Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 29th. Stifel Nicolaus lifted their price objective on Exelixis from $38.00 to $41.00 and gave the company a “hold” rating in a research note on Tuesday, July 29th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $50.00 price objective on shares of Exelixis in a research note on Tuesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.06.

Exelixis Stock Down 1.5%

EXEL stock opened at $37.70 on Thursday. The business has a 50 day moving average price of $40.25 and a 200 day moving average price of $39.60. The stock has a market cap of $10.15 billion, a price-to-earnings ratio of 18.13, a PEG ratio of 0.79 and a beta of 0.32. Exelixis, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The firm’s revenue was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.